Nautilus Biotechnology, Inc. Q3 FY2024 earnings call

• Sujal Patel highlighted the excitement in the proteomics space, progress in core platform development, and introduced Ken Suzuki as the first Chief Marketing Officer.
• Parag Mallick discussed participation in the World HUPO Congress, progress in proteoform detection, and the platform's capabilities for both targeted proteoform quantification and broad scale discovery.
• Anna Mowry provided financial details, noting tight operating expenses, cash balance, and commitment to tight spend management to maximize cash runway.

No detailed financial performance by product segments provided in the transcript, as the company is in the early stages of platform development and no specific product segment financials are broken down.

• Anticipate commercial launch of the broad scale product in late 2025.
• Expect a lower burn rate and higher cash balance into 2027, with cash runway extending to 2027.
• Focus on proteoform engagements in the first half of 2025 to inform roadmap and pricing strategies, with the early access program for broad scale planned for the second half of 2025.

• Potential delays in reaching the broad scale discovery milestone of quantifying a significant number of proteins from complex samples.
• Higher than expected fallout rate for affinity probe candidates, with ongoing work to improve probe yield.
• Market and capital spend uncertainties that could impact sales cycles and customer adoption.

Q: Elaborate on the reasons for higher than expected fallout rate for affinity probe candidates and ways to address these issues?

A: Parag Mallick discussed extensive characterization of probes, noting a wide distribution of kinetics, and Sujal Patel added that the company is focused on development work streams to improve probe yield.

Q: Update on proteoform capabilities towards launch and their availability to early access customers?

A: Sujal Patel explained that the first half of 2025 will focus on proteoform engagements using tau as a litmus test, with the early access program for broad scale planned for the second half of 2025.

Q: What metrics will be used to track corporate goals in 2025 and where will investment be increased?

A: Sujal and Anna Mowry discussed metrics related to development milestones and tight spend management, with targeted investments in the commercial team as the product nears launch.

Q: Interest in discovery vs targeted side and sizing of potential opportunities?

A: Sujal Patel discussed excitement in broad scale proteomics and the need for progress in the first half of 2025 to better size the proteoform opportunity.

Q: Breaking into the market with established players and competition?

A: Parag Mallick and Sujal Patel discussed the platform's advantages over existing players, including sensitivity, dynamic range, and accessibility, highlighting its disruptive potential in proteomics.

Q: Thoughts on pricing and market interpretation?

A: Sujal Patel noted the positive reception of high-end mass spec instruments, supporting the expected initial deal size and indicating continued focus on finalizing pricing and business model.

Q: Academic gov funding landscape and customer mix post-launch?

A: Sujal Patel discussed mixed funding trends and expected customer mix including academic, non-profit, and pharma customers.

Q: Broad scale milestone progress and probe labeling shift?

A: Sujal Patel discussed efforts to reach the broad scale milestone, with progress in labeling strategy and focus on improving probe yield.

Q: Commercial launch timeline?

A: Sujal Patel explained the continued plan for late 2025 launch, with ongoing efforts to achieve the milestone despite potential delays